CytoSolve® Enables Peer-Reviewed Systems Architecture for Mechanistic Modeling of Neuromyelitis Optica at UCLA

Partner Description

University of California, Los Angeles (UCLA)
UCLA is a leading academic medical and research institution with deep expertise in neuroimmunology and autoimmune disease. UCLA investigators study the molecular and cellular mechanisms underlying neuromyelitis optica (NMO), with particular focus on immune-mediated central nervous system inflammation and antibody-driven pathology, to advance translational discovery and therapeutic development.

Challenge

Neuromyelitis optica (NMO) arises from complex immune signaling interactions within the central nervous system, involving astrocytes, B cells, T cells, dendritic cells, and cytokine networks triggered by anti–aquaporin-4 (AQP4) IgG antibodies. These interactions generate emergent behaviors that are difficult to capture using single-pathway analyses or isolated experimental systems.

UCLA researchers faced several barriers:

  • Human immune complexity: Dynamic, multi-cell signaling interactions could not be adequately represented using reductionist pathway diagrams.
  • Limitations of animal models: Species-specific immune differences constrained the translational relevance of mammalian model systems.
  • Need for mechanistic integration: Existing pathway “blueprints” describing NMO biology required formal computational representation to become testable, extensible, and suitable for peer-review validation.
A systems-level, human-pathway-centered framework was required to integrate immune signaling across cell types while preserving mechanistic transparency and scientific rigor.

How CytoSolve® Helped

CytoSolve® collaborated with UCLA investigators to transform conceptual immune-pathway blueprints of NMO into a peer-review-ready computational systems architecture composed of interoperable in silico models.

Using CytoSolve®’s modular integration engine, molecular pathways implicated in NMO were encoded as mechanistic computational models with explicit signaling logic and defined interconnections. The architecture supported multi-compartment, multi-cell modeling, capturing signal transduction and cross-talk among astrocytes, dendritic cells, T cells, and B cells—cell populations central to NMO pathology.

Rather than evaluating immune pathways in isolation, CytoSolve® dynamically integrated them into a unified computational context, enabling system-level interrogation of immune behavior. The framework explicitly incorporated anti-AQP4 IgG–driven perturbations as mechanistic triggers, allowing investigators to simulate downstream inflammatory cascades and immune amplification effects.

Model outputs were structured around cytokine-level readouts, linking antibody-driven signaling to predicted activation patterns in interleukins-2, -4, -8, -10, and -13. This design supported hypothesis generation, mechanistic interpretation, and prioritization of therapeutic intervention concepts grounded in integrated pathway behavior.

Key Benefits Realized

  • Peer-review-ready systems architecture integrating CNS-relevant immune cell interactions.
  • Mechanistic, system-level interpretation of NMO immune signaling beyond single-pathway views.
  • Explicit modeling of astrocyte–immune cell cross-talk driving CNS inflammation.
  • In silico perturbation capability to explore antibody-driven immune activation.
  • Cytokine-level linkage connecting anti-AQP4 IgG activity to downstream inflammatory signatures.
  • Improved translational relevance through a human-pathway-centered modeling framework.

Outcome

Through the CytoSolve® collaboration, UCLA established an integrated, mechanistic in silico platform for studying neuromyelitis optica as a coordinated, multi-cell immune signaling disease. The resulting peer-validated systems architecture enabled investigators to examine how anti-AQP4 IgG can propagate cytokine activation and immune amplification across astrocytes and immune populations. This work strengthened hypothesis generation, informed experimental design, and supported therapeutic prioritization—demonstrating CytoSolve®’s value as a peer-review-grade systems biology infrastructure for complex neuroimmune diseases.